BRCA1 and breast cancer: In the INFORM trial, neoadjuvant single-agent cisplatin did not yield superior pCR rates when compared to the combination of doxorubicin and cyclophosphamide in patients with HER2 negative early BC who carry BRCA1/2 mutations (96).